Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 2/20 | 0.56 |
| ▸ | CPA1 | P15085 | 2/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | FPR2 | P25090 | 4/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012053 | 1.00 | MME (0.63) | MMENPSR1NAALAD2L3MBTL1ACE | |
| SCHEMBL1012023 | 1.00 | MME (0.63) | MMENPSR1NAALAD2L3MBTL1ACE | |
| Hydrochloric Acid SCHEMBL1262435 | 0.98 | MME (0.61) | MMENPSR1NAALAD2L3MBTL1ACE | |
| Ammonia Solution, Strong SCHEMBL10824808 | 0.98 | MME (0.61) | MMENPSR1NAALAD2L3MBTL1ACE | |
| Ammonia Solution, Strong SCHEMBL10824805 | 0.98 | MME (0.61) | MMENPSR1NAALAD2L3MBTL1ACE | |
| SCHEMBL6853867 | 0.89 | HPGDS (0.56) | MMEPOLBSMN1; SMN2 | |
| SCHEMBL26527726 | 0.86 | NAALAD2 (0.61) | MMENPSR1NAALAD2L3MBTL1FPR2 | |
| SCHEMBL8072837 | 0.86 | MME (0.60) | MMEACECPA1ACE2 | |
| SCHEMBL3829705 | 0.86 | FOLH1 (0.61) | MMENAALAD2L3MBTL1ACECPA1 | |
| SCHEMBL1498340 | 0.86 | MME (0.59) | MMENPSR1NAALAD2L3MBTL1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | claimed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | claimed |
| EP-1001764-A4 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2005-08-24 | — | — | EP | claimed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | claimed |
| JP-2002512625-A | — | — | 2002-04-23 | — | — | JP | claimed |
| EP-1001764-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999064395-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1998053814-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | claimed |
| CN-1100426-A | Lysosomal enzyme-cleavable antitumor drug conjugates | BRISTOL MYERS SQUIBB CO (US) | 1995-03-22 | — | — | CN | claimed |
| JP-63054342-A | — | — | None | — | — | JP | disclosed |
| JP-60011457-A | — | — | None | — | — | JP | disclosed |
| JP-1139560-A | — | — | None | — | — | JP | disclosed |
| JP-61122261-A | — | — | None | — | — | JP | disclosed |
| JP-61148156-A | — | — | None | — | — | JP | disclosed |
| EP-0071395-A1 | Beta-lactam antibacterial agents | BEECHAM GROUP PLC (GB) | 1983-02-09 | — | — | EP | disclosed |
| US-4277404-A | INTERMEDIATES FOR TRANQUILIZERS | PFIZER INC. (US) | 1981-07-07 | — | — | US | disclosed |
| US-4267331-A | REDUCTIVE ALKYLATION OF A 5-PHENYL-2,3,4,4A,5,9B-HEXAHYDRO-1H-PYRIDO/4,3-B/INDOLE WITH A REDUCING AGENT AND A 2-HYDROXY-5- OR 6-PHENYLFURAN OR -PYRAN | PFIZER INC. (US) | 1981-05-12 | — | — | US | disclosed |
| US-4252812-A | TRANQUILIZERS | PFIZER INC. (US) | 1981-02-24 | — | — | US | disclosed |
| US-4224329-A | TRANQUILIZERS | PFIZER INC. (US) | 1980-09-23 | — | — | US | disclosed |
| JP-S06363395-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | MME 373/4885NPSR1 594/4885NAALAD2 4017/4885 |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | MME 109/4885NPSR1 1180/4885NAALAD2 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.